This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rettig, W. J. Articles by Old, L. J. Search for Related Content PubMed PubMed Citation Articles by Rettig, W. J. Articles by Old, L. J.

Regulation and Heteromeric Structure of the Fibroblast Activation Protein in Normal and Transformed Cells of Mesenchymal and Neuroectodermal Origin¹

Immunology Program [W. J. R., S. L. S., A. P. A.], Ludwig Institute for Cancer Research [P. G-C., L. J. O.], Departments of Pathology [P. G. C.] and Surgery [J. H. H.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School, Newark, New Jersey 07103 [H. L. O.]; and Deutsches Krebsforschungszentrum, Heidelberg, Germany [M. S.]

The human fibroblast activation protein (FAP), defined by monoclonal antibody F19, is expressed in vivo in reactive stromal fibroblasts of epithelial cancers, subsets of bone and soft tissue sarcomas, and granulation tissue of healing wounds. FAP is generally absent from the stroma of benign epithelial tumors and normal adult tissues. In vitro FAP induction is observed in proliferating cultured fibroblasts and in melanocytes grown with fibroblast growth factor and phorbol ester. In the present study, we show that fibroblast and melanocyte FAP is a cell surface protein comprising noncovalently linked M_r 95,000 (p95) and M_r 105,000 (p105) subunits. In contrast, cultured sarcoma and melanoma cell lines express only p95 or are FAP negative. Immunoblot experiments show that p95, but not p105, carries the epitope defined by monoclonal antibody F19. Furthermore, peptide maps of purified p95 and p105 differ, suggesting that they may be distinct gene products. Loss of FAP or a change from p95/p105 to p95 expression accompanies the acquisition of growth factor independence and tumorigenicity in several in vitro test systems, including simian virus 40 transformation of normal fibroblasts, Ha-ras transformation of normal melanocytes, supertransformation of osteosarcoma cells, and enhanced N-MYC expression in variant neuroblastoma cells, whereas serum-starved normal fibroblasts continue to express p95/p105. Thus, FAP expression appears to be linked to the growth factor-dependent proliferative capacity of normal cells and is not merely a secondary event in proliferating cells; furthermore, FAP expression is inversely correlated with growth factor independence and tumorigenicity in transformed cell lines. This distribution pattern is consistent with a role for p95/p105 in mediating extrinsic, growth regulatory signals in normal cells, possibly as a heteromeric cell surface receptor. Such a physiological function may be obviated when oncogenes with cytoplasmic or nuclear sites of action are activated, reducing extrinsic growth factor dependence and permitting down-regulation of FAP in certain transformed cells.

¹ This work was supported in part by the National Cancer Institute (CA-57486, CA-41520, CA-37907), the National Institute on Aging (AG-04821), the Jennie R. and Oliver S. Donaldson Charitable Fund, and the New York City Marathon Fund.

² To whom requests for reprints should be addressed, at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Received 2/16/93. Accepted 5/12/93.

This article has been cited by other articles:

				E. Ostermann, P. Garin-Chesa, K. H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W. J. Rettig, and G. R. Adolf Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts Clin. Cancer Res., July 15, 2008; 14(14): 4584 - 4592. [Abstract] [Full Text] [PDF]

				C. Y. Edosada, C. Quan, C. Wiesmann, T. Tran, D. Sutherlin, M. Reynolds, J. M. Elliott, H. Raab, W. Fairbrother, and B. B. Wolf Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity J. Biol. Chem., March 17, 2006; 281(11): 7437 - 7444. [Abstract] [Full Text] [PDF]

				J. Lee, M. Fassnacht, S. Nair, D. Boczkowski, and E. Gilboa Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts Cancer Res., December 1, 2005; 65(23): 11156 - 11163. [Abstract] [Full Text] [PDF]

				K. Tahtis, F.-T. Lee, J. M. Wheatley, P. Garin-Chesa, J. E. Park, F. E. Smyth, Y. Obata, E. Stockert, C. M. Hall, L. J. Old, et al. Expression and Targeting of Human Fibroblast Activation Protein in a Human Skin/Severe Combined Immunodeficient Mouse Breast Cancer Xenograft Model Mol. Cancer Ther., August 1, 2003; 2(8): 729 - 737. [Abstract] [Full Text] [PDF]

				J. D. Cheng and L. M. Weiner Tumors and Their Microenvironments: Tilling the Soil: Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clin. Cancer Res., May 1, 2003; 9(5): 1590 - 1595. [Full Text] [PDF]

				A. M. Scott, G. Wiseman, S. Welt, A. Adjei, F.-T. Lee, W. Hopkins, C. R. Divgi, L. H. Hanson, P. Mitchell, D. N. Gansen, et al. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1639 - 1647. [Abstract] [Full Text] [PDF]

				J. E. Park, M. C. Lenter, R. N. Zimmermann, P. Garin-Chesa, L. J. Old, and W. J. Rettig Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts J. Biol. Chem., December 17, 1999; 274(51): 36505 - 36512. [Abstract] [Full Text] [PDF]

				M. J. Page, B. Amess, R. R. Townsend, R. Parekh, A. Herath, L. Brusten, M. J. Zvelebil, R. C. Stein, M. D. Waterfield, S. C. Davies, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties PNAS, October 26, 1999; 96(22): 12589 - 12594. [Abstract] [Full Text] [PDF]

				U. V. Wesley, A. P. Albino, S. Tiwari, and A. N. Houghton A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells J. Exp. Med., August 2, 1999; 190(3): 311 - 322. [Abstract] [Full Text] [PDF]

				W. Rettig, H. Erickson, A. Albino, and P Garin-Chesa Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways J. Cell Sci., January 2, 1994; 107(2): 487 - 497. [Abstract] [PDF]